Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets
Altimmune, Inc. (NASDAQ: ALT) is back in the biotech spotlight on December 17, 2025—less because the company suddenly became “safe,” and more because it’s heading into the kind of binary stretch that turns small-cap biotech charts into roller coasters: a high-stakes clinical update is expected before year-end, leadership is changing hands, and Wall Street price targets remain dramatically spread out.
Shares were indicated around $5.03 early Wednesday, after closing at roughly the same level on Tuesday (Dec. 16). [1]
Altimmune stock price action: why traders keep circling ALT
ALT has been showing the classic behavior of a catalyst-driven biotech: sharp moves on relatively light news flow, then drifting while investors wait for the…
